Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Alzheimer's Disease

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 100 articles:
HTML format
Text format



Single Articles


    April 2019
  1. ARVANITAKIS Z, Capuano AW
    Author response: Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology.
    Neurology. 2019;92:732.
    PubMed     Text format    


  2. LATTANZI S, Silvestrini M
    Reader response: Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology.
    Neurology. 2019;92:731.
    PubMed     Text format    


  3. SIEGLER JE 3RD, Galetta S
    Editors' note: Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology.
    Neurology. 2019;92:731.
    PubMed     Text format    


  4. MEYER PF, Tremblay-Mercier J, Leoutsakos J, Madjar C, et al
    INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.
    Neurology. 2019 Apr 5. pii: WNL.0000000000007232.
    PubMed     Text format     Abstract available


  5. HERSHEY LA, Lipton RB
    Naproxen for presymptomatic Alzheimer disease: Is this the end, or shall we try again?
    Neurology. 2019 Apr 5. pii: WNL.0000000000007233.
    PubMed     Text format    


  6. KANG SW, Jeon S, Yoo HS, Chung SJ, et al
    Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction.
    Neurology. 2019 Apr 3. pii: WNL.0000000000007373.
    PubMed     Text format     Abstract available


    March 2019
  7. CANNON-ALBRIGHT LA, Foster NL, Schliep K, Farnham JM, et al
    Relative risk for Alzheimer disease based on complete family history.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007231.
    PubMed     Text format     Abstract available


  8. VAN HARTEN AC
    Longevity gene KLOTHO may play a role in Alzheimer disease.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007302.
    PubMed     Text format    


  9. VOS SJB, Duara R
    The prognostic value of ATN Alzheimer biomarker profiles in cognitively normal individuals.
    Neurology. 2019 Mar 6. pii: WNL.0000000000007223.
    PubMed     Text format    


  10. MESULAM MM, Lalehzari N, Rahmani F, Ohm D, et al
    Cortical cholinergic denervation in primary progressive aphasia with Alzheimer pathology.
    Neurology. 2019 Mar 6. pii: WNL.0000000000007247.
    PubMed     Text format     Abstract available


    February 2019
  11. FEMMINELLA GD, Dani M, Wood M, Fan Z, et al
    Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume.
    Neurology. 2019 Feb 22. pii: WNL.0000000000007133.
    PubMed     Text format     Abstract available


  12. ESPAY AJ, Vizcarra JA, Marsili L, Lang AE, et al
    Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.
    Neurology. 2019;92:329-337.
    PubMed     Text format     Abstract available


    January 2019
  13. OSSENKOPPELE R, Smith R, Ohlsson T, Strandberg O, et al
    Associations between tau, Abeta, and cortical thickness with cognition in Alzheimer disease.
    Neurology. 2019 Jan 9. pii: WNL.0000000000006875.
    PubMed     Text format     Abstract available


  14. KANTARCI K, Jicha GA
    Development of (1)H MRS biomarkers for tracking early predementia Alzheimer disease.
    Neurology. 2019 Jan 4. pii: WNL.0000000000006839.
    PubMed     Text format    


    December 2018
  15. HARA Y, McKeehan N, Fillit HM
    Translating the biology of aging into novel therapeutics for Alzheimer disease.
    Neurology. 2018 Dec 7. pii: WNL.0000000000006745.
    PubMed     Text format     Abstract available


    October 2018
  16. GROOT C, Sudre CH, Barkhof F, Teunissen CE, et al
    Clinical phenotype, atrophy, and small vessel disease in APOEepsilon2 carriers with Alzheimer disease.
    Neurology. 2018 Oct 19. pii: WNL.0000000000006503.
    PubMed     Text format     Abstract available


  17. KORK F, Jankowski J, Goswami A, Weis J, et al
    Golgin A4 in CSF and granulovacuolar degenerations of Alzheimer patients.
    Neurology. 2018 Oct 10. pii: WNL.0000000000006457.
    PubMed     Text format     Abstract available


    September 2018
  18. BRICKMAN AM, Tosto G, Gutierrez J, Andrews H, et al
    An MRI measure of degenerative and cerebrovascular pathology in Alzheimer disease.
    Neurology. 2018 Sep 14. pii: WNL.0000000000006310.
    PubMed     Text format     Abstract available


  19. MCDADE E, Wang G, Gordon BA, Hassenstab J, et al
    Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.
    Neurology. 2018 Sep 14. pii: WNL.0000000000006277.
    PubMed     Text format     Abstract available


    August 2018
  20. DICKSON DW, Heckman MG, Murray ME, Soto AI, et al
    APOE epsilon4 is associated with severity of Lewy body pathology independent of Alzheimer pathology.
    Neurology. 2018 Aug 24. pii: WNL.0000000000006212.
    PubMed     Text format     Abstract available


  21. PETERSEN RC
    How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture.
    Neurology. 2018 Aug 8. pii: WNL.0000000000006088.
    PubMed     Text format     Abstract available


  22. ASCHENBRENNER AJ, Gordon BA, Benzinger TLS, Morris JC, et al
    Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease.
    Neurology. 2018 Aug 1. pii: WNL.0000000000006075.
    PubMed     Text format     Abstract available


    July 2018

  23. Age-dependent white matter inflammation and cognitive impairment in the TgAPP21 rat model of Alzheimer disease.
    Neurology. 2018;91:242.
    PubMed     Text format    


  24. JANELIDZE S, Mattsson N, Stomrud E, Lindberg O, et al
    CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease.
    Neurology. 2018 Jul 27. pii: WNL.0000000000006082.
    PubMed     Text format     Abstract available


  25. JANG H, Bae JB, Dardiotis E, Scarmeas N, et al
    Differential effects of completed and incomplete pregnancies on the risk of Alzheimer disease.
    Neurology. 2018 Jul 18. pii: WNL.0000000000006000.
    PubMed     Text format     Abstract available


  26. ARVANITAKIS Z, Capuano AW, Lamar M, Shah RC, et al
    Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology.
    Neurology. 2018 Jul 11. pii: WNL.0000000000005951.
    PubMed     Text format     Abstract available


    June 2018
  27. STRAIN JF, Smith RX, Beaumont H, Roe CM, et al
    Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions.
    Neurology. 2018 Jun 29. pii: WNL.0000000000005864.
    PubMed     Text format     Abstract available


  28. MERLUZZI AP, Carlsson CM, Johnson SC, Schindler SE, et al
    Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia.
    Neurology. 2018 Jun 29. pii: WNL.0000000000005901.
    PubMed     Text format     Abstract available


  29. BENARROCH EE
    Glutamatergic synaptic plasticity and dysfunction in Alzheimer disease: Emerging mechanisms.
    Neurology. 2018 Jun 13. pii: WNL.0000000000005807.
    PubMed     Text format    


    April 2018
  30. PASSAMONTI L, Rodriguez PV, Hong YT, Allinson KSJ, et al
    [(11)C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy.
    Neurology. 2018 Apr 27. pii: WNL.0000000000005610.
    PubMed     Text format     Abstract available


  31. CUMMINGS JL, Cohen S, van Dyck CH, Brody M, et al
    ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005550.
    PubMed     Text format     Abstract available


  32. BERTI V, Walters M, Sterling J, Quinn CG, et al
    Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults.
    Neurology. 2018 Apr 13. pii: WNL.0000000000005527.
    PubMed     Text format     Abstract available


  33. KERN S, Zetterberg H, Kern J, Zettergren A, et al
    Prevalence of preclinical Alzheimer disease: Comparison of current classification systems.
    Neurology. 2018 Apr 13. pii: WNL.0000000000005476.
    PubMed     Text format     Abstract available


    March 2018
  34. ARENAZA-URQUIJO EM, Vemuri P
    Resistance vs resilience to Alzheimer disease: Clarifying terminology for preclinical studies.
    Neurology. 2018 Mar 28. pii: WNL.0000000000005303.
    PubMed     Text format     Abstract available


    February 2018
  35. BENNETT DA, Gordon BA
    Alzheimer disease biomarkers and synucleinopathy.
    Neurology. 2018 Feb 21. pii: WNL.0000000000005171.
    PubMed     Text format    


  36. MENDES A, Bertrand A, Lamari F, Colliot O, et al
    Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasias.
    Neurology. 2018 Feb 14. pii: WNL.0000000000005165.
    PubMed     Text format     Abstract available


  37. BOTHA H, Mantyh WG, Graff-Radford J, Machulda MM, et al
    Tau-negative amnestic dementia masquerading as Alzheimer disease dementia.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005124.
    PubMed     Text format     Abstract available


  38. KNOPMAN DS
    Sifting through a failed Alzheimer trial: What biomarkers tell us about what happened.
    Neurology. 2018 Feb 2. pii: WNL.0000000000005073.
    PubMed     Text format    


    January 2018
  39. AISEN PS
    Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Neurology. 2018;90:145.
    PubMed     Text format    


  40. PIAZZA F
    Reader response: A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Neurology. 2018;90:144-145.
    PubMed     Text format    


  41. KARAM C, Griggs RC
    Editors' note: A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Neurology. 2018;90:144.
    PubMed     Text format    


  42. MATTSSON N, Smith R, Strandberg O, Palmqvist S, et al
    Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease.
    Neurology. 2018 Jan 10. pii: WNL.0000000000004887.
    PubMed     Text format     Abstract available


    December 2017
  43. WILLIAMS DM, Karlsson IK, Pedersen NL, Hagg S, et al
    Circulating insulin-like growth factors and Alzheimer disease: A mendelian randomization study.
    Neurology. 2017 Dec 27. pii: WNL.0000000000004854.
    PubMed     Text format     Abstract available


  44. YASAR S, Whitmer R
    Statin use and risk of Alzheimer disease: A new view on an old relationship.
    Neurology. 2017 Dec 15. pii: WNL.0000000000004837.
    PubMed     Text format    


  45. SINYAVSKAYA L, Gauthier S, Renoux C, Dell'Aniello S, et al
    Comparative effect of statins on the risk of incident Alzheimer disease.
    Neurology. 2017 Dec 15. pii: WNL.0000000000004818.
    PubMed     Text format     Abstract available


  46. GROOT C, van Loenhoud AC, Barkhof F, van Berckel BNM, et al
    Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease.
    Neurology. 2017 Dec 13. pii: WNL.0000000000004802.
    PubMed     Text format     Abstract available


  47. GONNEAUD J, Arenaza-Urquijo EM, Mezenge F, Landeau B, et al
    Increased florbetapir binding in the temporal neocortex from age 20 to 60 years.
    Neurology. 2017;89:2438-2446.
    PubMed     Text format     Abstract available


    November 2017
  48. GROTHE MJ, Barthel H, Sepulcre J, Dyrba M, et al
    In vivo staging of regional amyloid deposition.
    Neurology. 2017;89:2031-2038.
    PubMed     Text format     Abstract available


  49. CORRIVEAU RA, Koroshetz WJ, Gladman JT, Jeon S, et al
    Alzheimer's Disease-Related Dementias Summit 2016: National research priorities.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004717.
    PubMed     Text format     Abstract available


    October 2017
  50. GAUTHIER S, Ng KP, Pascoal TA, Mathotaarachchi S, et al
    Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
    Neurology. 2017;89:1931.
    PubMed     Text format    


  51. LANDIN-ROMERO R, Kumfor F
    Letter re: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
    Neurology. 2017;89:1931.
    PubMed     Text format    


  52. RISACHER SL, Anderson WH, Charil A, Castelluccio PF, et al
    Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline.
    Neurology. 2017 Oct 25. pii: 10.1212/WNL.0000000000004670.
    PubMed     Text format     Abstract available


  53. WESTON PSJ, Poole T, Ryan NS, Nair A, et al
    Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration.
    Neurology. 2017 Oct 25. pii: 10.1212/WNL.0000000000004667.
    PubMed     Text format     Abstract available


  54. FILIPPI M, Basaia S, Canu E, Imperiale F, et al
    Brain network connectivity differs in early-onset neurodegenerative dementia.
    Neurology. 2017;89:1764-1772.
    PubMed     Text format     Abstract available


  55. BRENOWITZ WD, Hubbard RA, Keene CD, Hawes SE, et al
    Mixed neuropathologies and associations with domain-specific cognitive decline.
    Neurology. 2017;89:1773-1781.
    PubMed     Text format     Abstract available


  56. CHETELAT G, Murray ME
    Amyloid PET scan: Staging beyond reading?
    Neurology. 2017 Oct 18. pii: 10.1212/WNL.0000000000004678.
    PubMed     Text format    


  57. KIEBOOM BCT, Licher S, Wolters FJ, Ikram MK, et al
    Serum magnesium is associated with the risk of dementia.
    Neurology. 2017;89:1716-1722.
    PubMed     Text format     Abstract available


  58. ROBERTS RO, Knopman DS, Syrjanen JA, Aakre JA, et al
    Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers.
    Neurology. 2017 Oct 13. pii: 10.1212/WNL.0000000000004652.
    PubMed     Text format     Abstract available


  59. GASBY D
    Alzheimer dementia's other victim: The spouse.
    Neurology. 2017 Oct 6. pii: 10.1212/WNL.0000000000004638.
    PubMed     Text format    


  60. WEINER MW, Crane PK, Montine TJ, Bennett DA, et al
    Traumatic brain injury may not increase the risk of Alzheimer disease.
    Neurology. 2017 Oct 4. pii: 10.1212/WNL.0000000000004608.
    PubMed     Text format     Abstract available


    September 2017
  61. MEDAGLIA JD, Huang W, Segarra S, Olm C, et al
    Brain network efficiency is influenced by the pathologic source of corticobasal syndrome.
    Neurology. 2017;89:1373-1381.
    PubMed     Text format     Abstract available


  62. CASALETTO KB, Elahi FM, Bettcher BM, Neuhaus J, et al
    Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers.
    Neurology. 2017 Sep 22. pii: 10.1212/WNL.0000000000004569.
    PubMed     Text format     Abstract available


  63. NORTON DJ, Amariglio R, Protas H, Chen K, et al
    Subjective memory complaints in preclinical autosomal dominant Alzheimer disease.
    Neurology. 2017 Sep 6. pii: 10.1212/WNL.0000000000004533.
    PubMed     Text format     Abstract available


    August 2017
  64. MOSCONI L, Berti V, Quinn C, McHugh P, et al
    Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging.
    Neurology. 2017 Aug 30. pii: 10.1212/WNL.0000000000004425.
    PubMed     Text format     Abstract available



  65. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.
    Neurology. 2017;89:980.
    PubMed     Text format    


  66. SMITH R, Scholl M, Widner H, van Westen D, et al
    In vivo retention of 18F-AV-1451 in corticobasal syndrome.
    Neurology. 2017;89:845-853.
    PubMed     Text format     Abstract available


  67. LI G, Mayer CL, Morelli D, Millard SP, et al
    Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults.
    Neurology. 2017 Aug 18. pii: 10.1212/WNL.0000000000004392.
    PubMed     Text format     Abstract available


    July 2017
  68. BENUSSI A, Di Lorenzo F, Dell'Era V, Cosseddu M, et al
    Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia.
    Neurology. 2017 Jul 26. pii: 10.1212/WNL.0000000000004232.
    PubMed     Text format     Abstract available


  69. DONADIO V, Incensi A, Rizzo G, Capellari S, et al
    A new potential biomarker for dementia with Lewy bodies: Skin nerve alpha-synuclein deposits.
    Neurology. 2017;89:318-326.
    PubMed     Text format     Abstract available


  70. LAFAILLE-MAGNAN ME, Poirier J, Etienne P, Tremblay-Mercier J, et al
    Odor identification as a biomarker of preclinical AD in older adults at risk.
    Neurology. 2017;89:327-335.
    PubMed     Text format     Abstract available


  71. SPIRA AP, Ju YS
    Self-reported sleep and Alzheimer disease CSF biomarkers: A wake-up call.
    Neurology. 2017 Jul 5. pii: 10.1212/WNL.0000000000004189.
    PubMed     Text format    


  72. MOFFAT SD
    Author response: Long-term cortisol measures predict Alzheimer disease risk.
    Neurology. 2017;89:106.
    PubMed     Text format    


  73. LATTANZI S, Silvestrini M
    Letter re: Long-term cortisol measures predict Alzheimer disease risk.
    Neurology. 2017;89:106.
    PubMed     Text format    


    June 2017
  74. ZHAN X
    Author response: Gram-negative bacterial molecules associate with Alzheimer disease pathology.
    Neurology. 2017;88:2338.
    PubMed     Text format    


  75. MENTE K
    Letter re: Gram-negative bacterial molecules associate with Alzheimer disease pathology.
    Neurology. 2017;88:2338.
    PubMed     Text format    


  76. BUCKLEY RF, Schultz AP, Hedden T, Papp KV, et al
    Functional network integrity presages cognitive decline in preclinical Alzheimer disease.
    Neurology. 2017 Jun 7. pii: 10.1212/WNL.0000000000004059.
    PubMed     Text format     Abstract available


  77. ALCOLEA D, Vilaplana E, Suarez-Calvet M, Illan-Gala I, et al
    CSF sAPPbeta, YKL-40, and neurofilament light in frontotemporal lobar degeneration.
    Neurology. 2017 Jun 7. pii: 10.1212/WNL.0000000000004088.
    PubMed     Text format     Abstract available


    May 2017
  78. GIANNINI LAA, Irwin DJ, McMillan CT, Ash S, et al
    Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia.
    Neurology. 2017 May 17. pii: 10.1212/WNL.0000000000004034.
    PubMed     Text format     Abstract available


  79. BOOTS EA, Schultz SA, Clark LR, Racine AM, et al
    BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention.
    Neurology. 2017 May 3. pii: 10.1212/WNL.0000000000003980.
    PubMed     Text format     Abstract available


    April 2017
  80. SCHULTZ SA, Boots EA, Darst BF, Zetterberg H, et al
    Cardiorespiratory fitness alters the influence of a polygenic risk score on biomarkers of AD.
    Neurology. 2017;88:1650-1658.
    PubMed     Text format     Abstract available


  81. NG KP, Pascoal TA, Mathotaarachchi S, Chung CO, et al
    Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
    Neurology. 2017 Apr 12. pii: 10.1212/WNL.0000000000003916.
    PubMed     Text format     Abstract available


  82. PETERSEN RC, Thomas RG, Aisen PS, Mohs RC, et al
    Randomized controlled trials in mild cognitive impairment: Sources of variability.
    Neurology. 2017 Apr 5. pii: 10.1212/WNL.0000000000003907.
    PubMed     Text format     Abstract available


  83. RELKIN NR, Thomas RG, Rissman RA, Brewer JB, et al
    A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Neurology. 2017 Apr 5. pii: 10.1212/WNL.0000000000003904.
    PubMed     Text format     Abstract available


    March 2017
  84. PAPP KV, Rentz DM, Mormino EC, Schultz AP, et al
    Cued memory decline in biomarker-defined preclinical Alzheimer disease.
    Neurology. 2017 Mar 10. pii: 10.1212/WNL.0000000000003812.
    PubMed     Text format     Abstract available


    February 2017
  85. DAY GS, Lim TS, Hassenstab J, Goate AM, et al
    Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease.
    Neurology. 2017 Feb 24. pii: 10.1212/WNL.0000000000003770.
    PubMed     Text format     Abstract available


  86. TOSTO G, Bird TD, Tsuang D, Bennett DA, et al
    Polygenic risk scores in familial Alzheimer disease.
    Neurology. 2017 Feb 17. pii: 10.1212/WNL.0000000000003734.
    PubMed     Text format     Abstract available


  87. IMTIAZ B, Tuppurainen M, Rikkonen T, Kivipelto M, et al
    Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study.
    Neurology. 2017 Feb 15. pii: 10.1212/WNL.0000000000003696.
    PubMed     Text format     Abstract available


  88. CHEN J, Yu JT, Wojta K, Wang HF, et al
    Genome-wide association study identifies MAPT locus influencing human plasma tau levels.
    Neurology. 2017;88:669-676.
    PubMed     Text format     Abstract available


  89. FRANZMEIER N, Duering M, Weiner M, Dichgans M, et al
    Left frontal cortex connectivity underlies cognitive reserve in prodromal Alzheimer disease.
    Neurology. 2017 Feb 10. pii: 10.1212/WNL.0000000000003711.
    PubMed     Text format     Abstract available


  90. KREISL WC, Lawrence R, Page E, Teich AF, et al
    11C-PBR28 PET detects translocator protein in a patient with astrocytoma and Alzheimer disease.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003693.
    PubMed     Text format    


    January 2017
  91. FEDOROVA TD, Seidelin LB, Knudsen K, Schacht AC, et al
    Decreased intestinal acetylcholinesterase in early Parkinson disease: An 11C-donepezil PET study.
    Neurology. 2017 Jan 18. pii: 10.1212/WNL.0000000000003633.
    PubMed     Text format     Abstract available


  92. THOMAS AJ, Attems J, Colloby SJ, O'Brien JT, et al
    Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB.
    Neurology. 2017;88:276-283.
    PubMed     Text format     Abstract available


    December 2016
  93. ENNIS GE, An Y, Resnick SM, Ferrucci L, et al
    Long-term cortisol measures predict Alzheimer disease risk.
    Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003537.
    PubMed     Text format     Abstract available


    November 2016
  94. MOKRY LE, Ross S, Morris JA, Manousaki D, et al
    Genetically decreased vitamin D and risk of Alzheimer disease.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003430.
    PubMed     Text format     Abstract available


  95. HOHMAN TJ, McLaren DG, Mormino EC, Gifford KA, et al
    Asymptomatic Alzheimer disease: Defining resilience.
    Neurology. 2016 Nov 4. pii: 10.1212/WNL.0000000000003397.
    PubMed     Text format     Abstract available


    October 2016
  96. KIKUCHI A, Okamura N, Hasegawa T, Harada R, et al
    In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET.
    Neurology. 2016 Oct 28. pii: 10.1212/WNL.0000000000003375.
    PubMed     Text format     Abstract available


  97. ZHAN X, Stamova B, Jin LW, DeCarli C, et al
    Gram-negative bacterial molecules associate with Alzheimer disease pathology.
    Neurology. 2016 Oct 26. pii: 10.1212/WNL.0000000000003391.
    PubMed     Text format     Abstract available


  98. WESTON PS, Nicholas JM, Lehmann M, Ryan NS, et al
    Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study.
    Neurology. 2016 Oct 12. pii: 10.1212/WNL.0000000000003322.
    PubMed     Text format     Abstract available


  99. MATTIS PJ, Niethammer M, Sako W, Tang CC, et al
    Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases.
    Neurology. 2016 Oct 5. pii: 10.1212/WNL.0000000000003285.
    PubMed     Text format     Abstract available


    September 2016
  100. MATTSSON N, Zetterberg H, Janelidze S, Insel PS, et al
    Plasma tau in Alzheimer disease.
    Neurology. 2016 Sep 30. pii: 10.1212/WNL.0000000000003246.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: